期刊
GENES
卷 14, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/genes14091807
关键词
cancer bioinformatics; aldehyde dehydrogenase; biomarkers; gene expression; leukemia; myeloid; acute
ALDH1A1 and ALDH2 were found to have the strongest association with AML patient risk group classification, and the sum of their RNA expression values was more strongly associated with AML patient risk group classification and survival than each gene alone. This suggests that ALDH1A1 and ALDH2 may serve as important targets for the treatment of high-risk AML patients.
It has been previously shown that the aldehyde dehydrogenase (ALDH) family member ALDH1A1 has a significant association with acute myeloid leukemia (AML) patient risk group classification and that AML cells lacking ALDH1A1 expression can be readily killed via chemotherapy. In the past, however, a redundancy between the activities of subgroup members of the ALDH family has hampered the search for conclusive evidence to address the role of specific ALDH genes. Here, we describe the bioinformatics evaluation of all nineteen member genes of the ALDH family as prospective actionable targets for the development of methods aimed to improve AML treatment. We implicate ALDH1A1 in the development of recurrent AML, and we show that from the nineteen members of the ALDH family, ALDH1A1 and ALDH2 have the strongest association with AML patient risk group classification. Furthermore, we discover that the sum of the expression values for RNA from the genes, ALDH1A1 and ALDH2, has a stronger association with AML patient risk group classification and survival than either one gene alone does. In conclusion, we identify ALDH1A1 and ALDH2 as prospective actionable targets for the treatment of AML in high-risk patients. Substances that inhibit both enzymatic activities constitute potentially effective pharmaceutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据